People: Furiex Pharmaceuticals Inc (FURX.O)
Dr. Paul S. Covington, M.D., is Senior Vice President - Clinical Development and Operations of Furiex Pharmaceuticals Inc., since January 2010. He is responsible for overseeing all regulatory and clinical operations of Furiex, including design and implementation of clinical trials for compounds in Furiex's pipeline. Dr. Covington joined PPD in 1991 and has more than 17 years of drug development experience. As PPD's executive vice president and chief medical officer, he designed and implemented the development programs for all PPD's compound partnering alliances. Dr. Covington was responsible for the Phase I and Phase II development of Priligy and alogliptin, both of which were partnered to pharmaceutical companies following completion of the Proof-of-Concept studies. He was at the forefront of establishing monitoring processes for patient safety and data integrity for complex studies involving extremely ill patients. Dr. Covington is well respected in the pharmaceutical industry and was often sought by clients of PPD for his knowledge in clinical trial design and development. During his career at PPD, Dr. Covington advised numerous pharmaceutical companies on drug development and regulatory strategies and supported companies at key FDA milestone meetings. Prior to joining PPD, Dr. Covington served in various medical roles in both hospital and private practice settings, where he was lead investigator in multiple protocols. He was medical director at Future HealthCare Research Centers in Birmingham, Ala., and chief of staff, director of cardio respiratory and director of critical care at Central Alabama Community Hospital. He completed his residency at Carraway Methodist Medical Center in Birmingham. Dr. Covington received his bachelor's and medical degrees from the University of Alabama in Birmingham.
|Total Annual Compensation, USD||Long-Term Incentive Plans, USD||All Other, USD||Fiscal Year Total, USD|